Q-omics provides the consensus-scored GH1 profile across patient tissues and cancer cell-line models. GH1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GH1 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, GH1 RNA expression shows 7,730 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, BLCA, and TGCT as cancer lineages where GH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GH1 survival associations across molecular data types. GH1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GH1 RNA expression–survival associations across cancer types. High GH1 expression shows unfavorable associations in ACC, LUSC, SCLC and LAML, but favorable associations in HNSC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GH1 RNA expression.
This table summarizes GH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GH1 shows lower tumor expression in BLCA, BRCA, COAD, KICH and UCEC and higher tumor expression in KIRC. The BLCA box plot shows higher GH1 RNA expression in normal versus tumor tissue (log2 FC = −0.096, t-test p = .003).
This table shows molecular features associated with GH1 in patient tissues and cancer cell lines. In patient samples, GH1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and KIDNEY.
